Research and Clinical Trials

The following are Industry Sponsored Clinical Research (ISR) currently conducted at the various centres. For further information, please contact the Principal Investigator.

TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Abdominal & Pelvic Hyperthermia in Treating Patients with Painful Unresectable Abdominal or Pelvic Malignancy ADIPOLAB-001 University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 017 268 0664
(Yok Yong)
N/A
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Bladder Cancer A Phase 3, Randomized, Open-Label Study to Evaluavate Perioperative Enfortumab Vedotin plus Pembrolizumab (MK-3475) versus Neodjuvant gemcitabine and cisplatin in cisplatin-eligible participants with muscle-invasive bladder cancer (KEYNOTE-B15/EV-304) KEYNOTE B15 University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD +6012 – 672 8761
(Cryst Sari – CS)
CLICK HERE
Bladder Cancer A Randomized phase 3 study evaluating cystectomy with perioperative pembrolizumab and cystectomy with perioperative enfortumab vedotin and pembrolizumab versus cystectomy alone in cisplatin-ineligible participants with muscle-invasive bladder cancer KEYNOTE 905 University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD +6012 – 672 8761
(Cryst Sari – CS)
CLICK HERE
Muscle-invasive bladder cancer A phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC) KEYNOTE 992 Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN +603 – 2615 5555, Ext. 1782
/ 1783
/ +60 17-233 6295 (Amirah)
CLICK HERE
Pulau Pinang Hospital DR SOO HOO HWOEI FEN +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD +6012 – 672 8761
(Cryst Sari – CS)
CLICK HERE
Sunway Medical Centre Dr Nik Muhd Aslan +603 – 74919191/ 603-8601 1079 CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Breast Cancer Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients with APOBEC3B AUROR University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 017 268 0664
(Yok Yong)
CLICK HERE
Triple Negative Breast Cancer A Phase III Double-blind Randomised Study Assesing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) CAPITELLO-290 University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 014 – 9337966
(Kimee Ku)
CLICK HERE
Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF +603 – 2296 0764
/ 0800
CLICK HERE
Breast Cancer Studies of Epigenetic changes in blood samples in breast cancer patients EPIGENECTIC University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 012 301 0042
(Alice)
N/A
HER2+ Breast Cancer A Two-part, Phase III, Multicenter, Randomized (1:1), Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2-Positive Advanced Breast Cancer with a PIK3CA Mutation EPIK-B2 Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF +603 – 2296 0764
/ 0800
CLICKH HERE
University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 014 – 9337966
(Kimee Ku)
CLICK HERE
Metastatic or Advanced Triple Negative Breast Cancer A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation EPIK-B3 Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF +603 – 2296 0764
/ 0800
CLICK HERE
University of Malaya Medical Centre (UMMC) DR ADLINDA ALIP 010 – 4346150
(Suganiya)
CLICK HERE
Beacon Hospital Sdn Bhd Dato’ Dr Mohamed Ibrahim A Wahid +603 – 7806 0845 CLICK HERE
Breast Cancer Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer EXEMASTANE University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 017 268 0664
(Yok Yong)
CLICK HERE
Breast Cancer A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer KEYNOTE B49 University of Malaya Medical Centre (UMMC) DR NUR FADHLINA ABDUL SATAR 014 – 9337966
(Kimee Ku)
CLICK HERE
HR+, HER2- Prospective Observational Study of Mobile App-Based Patient-Reported Outcomes In Advanced Brest Cancer in Asia MADELINE Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF +603 – 2296 0764
/ 0800
N//A
Metastatic breast cancer A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer RIGHT CHOICE Kuala Lumpur Hospital (HKL) DR MALWINDER SINGH SANDHU +603 – 2615 5555, Ext. 1782
/ 1783
CLICK HERE
Sarawak General Hospital DR VOON PEI JYE +608 – 2276 820 CLICK HERE
Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN +607 – 3565 155 CLICK HERE
Hospital Wanita dan Kanak-Kanak Sabah DR FLORA CHONG LI TZE +608 – 8522 600, Ext. 2272 CLICK HERE
Breast Cancer A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease SERENA-4 Pantai Hospital Kuala Lumpur DR JOHN LOW SENG HOOI +603 – 2296 0800 CLICK HERE
University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 014 – 9337966
(Kimee Ku)
010 236 1109
(Wei Ying)
CLICK HERE
Breast Cancer Phase II Study to assess the efficacy of Talazoparib in asian mEtastatic breast caNcer patients with a hOmologous Recombinant deficiency (HRD) signature (TENOR) TENOR University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 010 236 1109
(Wei Ying)
N/A
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Metastatic adenocarcinoma and squamous cell carcinoma of the esophagus A phase III randomized open-label study of single agent pembrolizumab vs physicians’ choice of single agent docetaxel, paclitaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus that have progressed after first-line standard therapy (KEYNOTE-181) MK3475-181 Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN +607 – 3565 155 CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Gastrointestinal Cancers Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers ASCOLT University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 014 – 9337966
(Kimee Ku)
012 301 0042
(Alice)
CLICK HERE
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma GLOW Kuala Lumpur Hospital (HKL) DR NOOR ZAFIFAH BINTI ZAKARIA +603 – 2615 5555, Ext. 1620
/ 1144
CLICK HERE
Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF +603 – 2296 0764
/ 0800
CLICK HERE
Pulau Pinang Hospital DR SOO HOO HWOEI FEN +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Hospital Wanita dan Kanak-Kanak Sabah DR SUCHARIT PONGPRAKYUN +608 – 8522 600, Ext. 2272 CLICK HERE
University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 010 236 1109
(Wei Ying)
CLICK HERE
Gastrointestinal Cancers A Phase 3 Double-blinded, two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Perticipants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation KEYNOTE 937 University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 012 301 0042
(Alice)
CLICK HERE
Gastrointestinal Cancers A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma KEYNOTE 966 University of Malaya Medical Centre (UMMC) DR WAN ZAMANIAH 010 – 4346150
(Suganiya)
CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Head & Neck Cancer The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head
and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line
Systemic Therapies for HNSCC (SEQ-HN).
KURA University of Malaya Medical Centre (UMMC) DR NUR FADHLINA ABDUL SATAR 014 – 9337966
(Kimee Ku)
CLICK HERE
Head and Neck Squamous Cell Carcinoma The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) KO-TIP-007 National Cancer Institute (IKN) DR SUHANA BINTI YUSAK +603 – 88925555, Ext. 4168 CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Non-small cell lung cancer A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) CANOPY A Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF +603 – 2296 0764
/ 0800
CLICK HERE
Hepatocellular Carcinoma A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) KEYNOTE-937 National Cancer Institute (IKN) DR WONG YOKE FUI, Florence +603 – 8892 5555, Ext. 4168 CLICK HERE
Sarawak General Hospital DR LIM YUEH NI +608 – 2276 820 CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Non-small cell lung cancer A Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer ARC-10 Pantai Hospital Kuala Lumpur DR JOHN LOW SENG HOOI +603 – 2296 0800 CLICK HERE
Universiti Kebangsaan Malaysian Medical Centre (UKMMC) PROF DATO’ DR FUAD ISMAIL +603 – 9145 5664 (SC) N/A
Non-small cell lung cancer Real-World Utilization and Outcomes with Dacomitinib First-Line Treatment for EGFR
Mutation-Positive Advanced Non-Small Cell Lung Cancer among Asian Patients – A Multi-Center Chart Review
ARIA Pantai Hospital Kuala Lumpur DR JOHN LOW SENG HOOI +603 – 2296 0800 CLICK HERE
Lung Cancer Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer ARTOG-OO4 University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 017 268 0664
(Yok Yong)
CLICK HERE
Lung Cancer (NSCLC) A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study). ATORG001 University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 017 268 0664
(Yok Yong)
010 236 1109
(Wei Ying)
CLICK HERE
Beacon Hospital Sdn Bhd Dr Azura Rozila Ahmad +603 – 7786 0845 CLICK HERE
Advanced or Metastatic NSCLC A single-arm, open-label, phase 2 study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation ATORG003 Beacon Hospital Sdn Bhd Dr Tho Lye Mun +603 – 7786 0845 CLICK HERE
Beacon Hospital Sdn Bhd Dr Azura Rozila Ahmad +603 – 7786 0845 CLICK HERE
Sarawak General Hospital DR LIM YUEH NI +608 – 2276 820 CLICK HERE
University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 017 268 0664
(Yok Yong)
CLICK HERE
Non-small cell lung cancer A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) CANOPY A Pulau Pinang Hospital DR TAN AI LIAN +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Sarawak General Hospital DR SYADWA BINTI ABDUL SHUKOR +608 – 2276 820 CLICK HERE
Non-small Cell Lung Cancer A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK301) in Combination with Platinum+Pemetrexed Chemotherapy in Subjects with First-Line Metastatic Non- squamous Non-Small Cell Lung Cancer [Protocol No. CK-301 301] CHECKPOINT Universiti Kebangsaan Malaysian Medical Centre (UKMMC) PROF DATO’ DR FUAD ISMAIL +603 – 9145 5664 (SC) N/A
Lung Cancer Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients – A Multi Center Chart Review DACOMITINIB University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 010 236 1109
(Wei Ying)
CLICK HERE
Non-small Cell Lung Cancer A Two Part Randomized Phase 3 Study of Combination of Cemiplimab (Anti-PDA-1 Antibody) and Platinum Based Doublet Chemotherapy in First Line Treatment of Patients with Advanced o Metastatic Non
Small Cell Lung Cancer
EMPOWER Universiti Kebangsaan Malaysian Medical Centre (UKMMC) PROF DATO’ DR FUAD ISMAIL +603 – 9145 5664 (SC) N/A
Advanced or Metastatic NSCLC A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study) INSIGHT-2 Beacon Hospital Sdn Bhd Dr Azura Rozila Ahmad +603 – 7786 0845 CLICK HERE
Sunway Medical Centre Dr Lim Boon Khaw +603 – 74919191/ 603-8601 1079 CLICK HERE
Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304) INCMGA 0012-304 Beacon Hospital Sdn Bhd Dr Azura Rozila Ahmad +603 -7786 0845 CLICK HERE
Tengku Ampuan Afzan Hospital, Kuantan DR AISHAH BINTI IBRAHIM +609 – 5572 922 CLICK HERE
Sarawak General Hospital DR AIDEN HENG FOOK YEW +608 – 2276 820 CLICK HERE
Non-Small Cell Lung Cancer (Stage III) Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive Non-Small Cell Lung Cancer (Stage III) whose disease has not progressed following definitive platinum-based chemoradiation therapy (LAURA) LAURA Kuala Lumpur Hospital (HKL) DR IBTISAM MUHAMAD NOR +603 – 2615 5555, Ext. 1620
/ 1144
CLICK HERE
University of Malaya Medical Centre (UMMC) DR ADLINDA ALIP 014 – 9337966
(Kimee Ku)
CLICK HERE
Beacon Hospital Sdn Bhd Dato’ Dr Mohamed Ibrahim A Wahid +603 – 7786 0845 CLICK HERE
Non-small Cell Lung Cancer A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/ Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671) MK-3475-671 Sarawak General Hospital DR AIDEN HENG FOOK YEW +608 – 2276 820 CLICK HERE
Advanced or Metastatic NSCLC A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine ML41262 Beacon Hospital Sdn Bhd Dr Tho Lye Mun +603 – 7786 0845 N/A
Non-Small Cell Lung Cancer A phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy MS200095-0031 Tengku Ampuan Afzan Hospital, Kuantan PROF DR HOW SOON HIN +609 – 5572 922 CLICK HERE
Pantai Hospital Kuala Lumpur DR THO LYE MUN +603 – 2296 0800 CLICK HERE
Sarawak General Hospital DR SYADWA BINTI ABDUL SHUKOR +608 – 2276 820 CLICK HERE
Pulau Pinang Hospital DR IRFHAN ALI B HYDER ALI +604 – 2225 767
/ 2225 762
/ 2225 766
CLICK HERE
Metastatic Non-Small Cell Lung Cancer A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) Mariposa Tengku Ampuan Afzan Hospital, Kuantan PROF DR HOW SOON HIN +609 – 5572 922 CLICK HERE
Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN +607 – 3565 155 CLICK HERE
Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN +603 – 2615 5555, Ext 1782
/ 1783
/ +60 17-233 6295 (Amirah)
CLICK HERE
Pulau Pinang Hospital DR SOO HOO HWOEI FEN +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Beacon Hospital Sdn Bhd Dr Azura Rozila Ahmad +603 – 7786 0845 CLICK HERE
University of Malaya Medical Centre (UMMC) DR ADLINDA ALIP 010 – 4346150
(Suganiya)
CLICK HERE
Metastatic Non-Small Cell Lung Cancer A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Papillon Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN +607 – 3565 155 CLICK HERE
Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN +603 – 2615 5555, Ext. 1782
/ 1783
/ +60 17-233 6295 (Amirah)
CLICK HERE
Pulau Pinang Hospital DR SOO HOO HWOEI FEN +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
University of Malaya Medical Centre (UMMC) DR ADLINDA ALIP +6012 – 672 8761
(Cryst Sari – CS)
CLICK HERE
Advanced NSCLC Real-world utilization and outcomes with “study drug” first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi-center chart review PFIZER A7471067 Beacon Hospital Sdn Bhd Dr Tho Lye Mun +603 – 7786 0845 CLICK HERE
Recurrent or Metastatic Non-squamous Non-small Cell Lung Cancer A Randomized, Double-blind, Parallel group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer SAMSON II Sunway Medical Centre Dr Nik Muhd Aslan +603 – 74919191/ 603-8601 1079 CLICK HERE
Non-small Cell Lung Cancer A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer STELLA Universiti Kebangsaan Malaysian Medical Centre (UKMMC) PROF DATO’ DR FUAD ISMAIL +603 – 9145 5664 (SC) N/A
Lung Cancer A phase 3 study to evaluate zimberelimab (AB122) monotherapy compared to standard chemotherapy of zimberelimab combined with AB154 in front-line, PDL1-Positive, locally advanced or metastatic non-small cell lung cancer ZIMBERELIMAB University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 012 301 0042
(Alice)
CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Ovarian Cancer A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer EPIK-O University of Malaya Medical Centre (UMMC) DR ROZITA ABDUL MALIK 017 268 0664
(Yok Yong)
CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Metastatic Prostate Cancer Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer 64091742PCR0002 Sarawak General Hospital DR HADI BIN AB.JALIL +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
/ 276 820
CLICK HERE
Pulau Pinang Hospital DR SOO HOO HWOEI FEN +604 – 2225 767
/ 2225 762
/ 2225 766
/ 2225 586
CLICK HERE
Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN +603 – 2615 5555, Ext. 1782
/ 1783
/ +60 17-233 6295 (Amirah)
CLICK HERE
Metastatic Castration-Sensitive Prostate Cancer Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) AMPLITUDE Kuala Lumpur Hospital (HKL) DR PRATHEPAMALAR A/P YEHGAMBARAM +603 – 2615 5555, Ext. 1620
/ 1144
CLICK HERE
Sarawak General Hospital DR HADI BIN AB.JALIL +608 – 227 6666
/ 6035
/ 276 820
CLICK HERE
National Cancer Institute (IKN) DR ARNIL GEORGE SIRIMANNE +603 – 8892 5555, Ext. 4168 CLICK HERE
Pulau Pinang Hospital DR FONG CHIN HENG +604 – 2225 767
/ 2225 762
/ 2225 766
CLICK HERE
University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD +6012 – 672 8761
(Cryst Sari – CS)
CLICK HERE
Metastic Prostate Cancer Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer MAGNITUDE University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD +6012 – 672 8761
(Cryst Sari – CS)
CLICK HERE
Hospital Wanita dan Kanak-Kanak Sabah Dr Flora Chong Li Tze +6088-522600, Ext. 2272 CLICK HERE
Prostate Cancer Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer PREVALENCE University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD +6012 – 672 8761
(Cryst Sari – CS)
CLICK HERE
Prostate Cancer A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients WithNonmetastatic Castration- Resistant Prostate Cancer PROSPER Universiti Kebangsaan Malaysian Medical Centre (UKMMC) PROF DATO’ DR FUAD ISMAIL +603 – 9145 5664 (SC) N/A
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Renal Cancer An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or
MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
MK6482-012 University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD +6012 – 672 8761
(Cryst Sari – CS)
CLICK HERE
TYPE TITLE SHORT TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Sarcoma/Solid Tumor Malignacies Immune Modulatory Effect of Hyperthermia During Treatment of Recurrent or Metastatic Solid Organ Malignancies ADIPOLAB-002 University of Malaya Medical Centre (UMMC) DR HO GWO FUANG 014 – 9337966
(Kimee Ku)
010 236 1109
(Wei Ying)
N/A

The information above was last updated on 19 August 2021.

Source: http://clinicalresearch.my/

Links are from CLINICALTRIAL.GOV